Name | Number of supported studies | Average coverage | |
---|---|---|---|
retina horizontal cell | 4 studies | 41% ± 16% |
Insufficient scRNA-seq data for expression of HS3ST3A1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 656.71 | 180 / 180 | 72% | 3.96 | 309 / 430 |
esophagus | 99% | 226.06 | 1431 / 1445 | 69% | 5.32 | 127 / 183 |
prostate | 99% | 300.65 | 243 / 245 | 62% | 1.51 | 312 / 502 |
lung | 92% | 103.83 | 534 / 578 | 63% | 2.73 | 724 / 1155 |
uterus | 85% | 108.40 | 144 / 170 | 58% | 5.19 | 266 / 459 |
intestine | 85% | 88.76 | 823 / 966 | 46% | 1.44 | 240 / 527 |
skin | 79% | 480.47 | 1422 / 1809 | 35% | 2.82 | 167 / 472 |
breast | 54% | 32.05 | 250 / 459 | 56% | 1.42 | 629 / 1118 |
stomach | 47% | 40.38 | 170 / 359 | 60% | 1.73 | 173 / 286 |
kidney | 96% | 120.21 | 85 / 89 | 10% | 1.01 | 94 / 901 |
adrenal gland | 90% | 138.51 | 233 / 258 | 15% | 0.91 | 34 / 230 |
spleen | 100% | 433.94 | 241 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 3.75 | 28 / 29 |
tonsil | 0% | 0 | 0 / 0 | 87% | 6.19 | 39 / 45 |
bladder | 43% | 34.52 | 9 / 21 | 39% | 1.63 | 197 / 504 |
pancreas | 2% | 0.82 | 5 / 328 | 70% | 2.80 | 124 / 178 |
heart | 64% | 94.13 | 552 / 861 | 0% | 0 | 0 / 0 |
thymus | 46% | 23.94 | 300 / 653 | 13% | 0.54 | 81 / 605 |
liver | 52% | 25.92 | 117 / 226 | 6% | 0.89 | 24 / 406 |
brain | 12% | 6.12 | 321 / 2642 | 30% | 1.23 | 212 / 705 |
adipose | 39% | 19.73 | 470 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 12% | 5.78 | 163 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 5% | 0.07 | 4 / 80 |
peripheral blood | 4% | 1.63 | 35 / 929 | 0% | 0 | 0 / 0 |
muscle | 2% | 1.13 | 19 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001658 | Biological process | branching involved in ureteric bud morphogenesis |
GO_0015015 | Biological process | heparan sulfate proteoglycan biosynthetic process, enzymatic modification |
GO_0006024 | Biological process | glycosaminoglycan biosynthetic process |
GO_0000139 | Cellular component | Golgi membrane |
GO_0016020 | Cellular component | membrane |
GO_0008467 | Molecular function | [heparan sulfate]-glucosamine 3-sulfotransferase 1 activity |
GO_0033872 | Molecular function | [heparan sulfate]-glucosamine 3-sulfotransferase 3 activity |
GO_0008146 | Molecular function | sulfotransferase activity |
Gene name | HS3ST3A1 |
Protein name | Sulfotransferase (EC 2.8.2.-) Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 (EC 2.8.2.30) (Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 3A1) (3-OST-3A) (Heparan sulfate 3-O-sulfotransferase 3A1) (h3-OST-3A) |
Synonyms | UNQ2551/PRO6180 3OST3A1 HS3ST3A |
Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to an N-unsubstituted glucosamine linked to a 2-O-sulfo iduronic acid unit on heparan sulfate . Catalyzes the O-sulfation of glucosamine in IdoUA2S-GlcNS and also in IdoUA2S-GlcNH2 . The substrate-specific O-sulfation generates an enzyme-modified heparan sulfate which acts as a binding receptor to Herpes simplex virus-1 (HSV-1) and permits its entry . Unlike HS3ST1/3-OST-1, does not convert non-anticoagulant heparan sulfate to anticoagulant heparan sulfate . . |
Accessions | ENST00000578576.1 J3KSX5 ENST00000284110.2 Q9Y663 |